Precisely. The economies of scale delivered by the NHS, together with the NICE regulatory framework, deliver enormous savings to the UK healthcare system. So much so, that in every discussion about a US-UK trade deal, the priority of the US government is for us to scrap that system so that US pharmaceutical companies can maximise profits.
There have been numerous studies which have concluded the UK system delivers better value for money for patients. The story below refers to one such study, looking at just 50 drugs, which concluded that the NHS (and therefore patients/taxpayers) would have to pay over £5bn more per year if we were paying US drug prices.
A new study has revealed that the NHS would spend billions more on drugs if it had to pay US prices following a UK/US trade deal.
www.hospitaltimes.co.uk